title: [Myopic CNV].
abstract: Choroidal neovascularisation secondary to pathological myopia is the most common cause of severe visual impairment in myopic patients younger than 50 years old. The typical features of myopic CNV in contrast to age-related macular degeneration as well as the anatomic characteristics have an impact on the parameters of the baseline and follow-up examinations. As the usually small fibrovascular lesions show a rapid progression in the spontaneous course of the disease and lead to irreversible damage to the photoreceptors, prompt initiation of treatment is mandatory. The superior functional results of anti-VEGF drugs provide the reason for the first-line status of this treatment modality. Increasing safety data and consistent results of prospective pilot trials have proved photodynamic therapy to be inferior. There are signs that PRN-based treatment algorithms may allow for less frequent dosing than in other retinal diseases.
authors.affiliation: Department für Augenheilkunde, Eberhard-Karl-Universität Tübingen.
authors.forename: B
authors.initials: B
authors.lastname: Voykov
authors.forename: F
authors.initials: F
authors.lastname: Ziemssen
mesh_terms: D000328:Adult; D000368:Aged; D000465:Algorithms; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use; D058452:Axial Length, Eye / Q000187:drug effects / Q000502:physiology; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000175:diagnosis* / Q000503:physiopathology / Q000628:therapy; D018450:Disease Progression; D005451:Fluorescein Angiography; D006801:Humans; D008268:Macular Degeneration / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy; D008875:Middle Aged; D009216:Myopia / Q000175:diagnosis* / Q000503:physiopathology / Q000628:therapy; D010778:Photochemotherapy; D020419:Photoreceptor Cells, Vertebrate / Q000187:drug effects / Q000502:physiology; D010865:Pilot Projects; D011379:Prognosis; D011446:Prospective Studies; D000069579:Ranibizumab; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000502:physiology; D014792:Visual Acuity / Q000187:drug effects / Q000502:physiology
chemical_list: D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab